Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
IKT | US
-0.22
-9.36%
Healthcare
Biotechnology
30/06/2024
18/10/2024
2.13
2.32
2.33
2.00
Inhibikase Therapeutics Inc. a clinical-stage pharmaceutical company develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009 a small molecule Abelson tyrosine kinase inhibitor which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics Inc. has research and development collaborations with Johns Hopkins University Arizona State University University of Bordeaux and Michigan State University as well as University of California; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is headquartered in Atlanta Georgia.
View LessPositive Momentum
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
High Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
137.3%1 month
114.7%3 months
86.4%6 months
112.4%-
-
3.44
0.03
0.02
0.34
2.75
-
-18.98M
15.90M
15.90M
-
-23.89K
-
-100.00
-149.69
2.37
0.67
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
1.36
Range1M
1.39
Range3M
1.39
Rel. volume
0.26
Price X volume
581.70K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
ICU | ICU | Biotechnology | 4.1 | 17.19M | 1.99% | n/a | -45.50% |
Kazia Therapeutics Limited | KZIA | Biotechnology | 0.5024 | 16.72M | -4.65% | n/a | 6.82% |
Synlogic Inc | SYBX | Biotechnology | 1.41 | 16.49M | -0.70% | n/a | 0.00% |
LYRA THERAPEUTICS INC | LYRA | Biotechnology | 0.2436 | 15.95M | 4.64% | n/a | 118.63% |
Evaxion Biotech A/S | EVAX | Biotechnology | 2.64 | 15.58M | -2.58% | n/a | 837.11% |
Indaptus Therapeutics Inc. Common Stock | INDP | Biotechnology | 1.5097 | 15.39M | -2.60% | n/a | 2.12% |
ImmunoPrecise Antibodies Ltd | IPA | Biotechnology | 0.54 | 15.13M | 0.19% | n/a | 49.00% |
Cara Therapeutics Inc | CARA | Biotechnology | 0.2651 | 14.97M | -0.64% | n/a | 406.66% |
IMNN | IMNN | Biotechnology | 0.9855 | 14.19M | 0.69% | n/a | 37.13% |
Apollomics Inc. Class A Ordinary Shares | APLM | Biotechnology | 0.1281 | 14.09M | 3.98% | n/a | 21.43% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 0.538 | 7.80M | -6.65% | 0.03 | 16.03% |
Forza X1 Inc | FRZA | Recreational Vehicles | 0.2201 | 3.95M | 4.26% | n/a | 0.97% |
EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.06 | 2.76M | 1.92% | n/a | 17.32% |
Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.01 | 897.66K | -12.28% | n/a | -37.05% |
Winnebago Industries Inc | WGO | Recreational Vehicles | 60.38 | 0 | 0.37% | 22.53 | 56.33% |
Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 3.92 | 0 | -8.84% | n/a | 0.00% |
Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.4801 | 0 | -10.26% | n/a | 19.98% |
Urban One Inc | UONEK | Broadcasting - Radio | 1.045 | 0 | -2.34% | n/a | 268.43% |
Virco Mfg. Corporation | VIRC | Building Products & Equipment | 14.82 | 0 | 1.93% | 9.09 | 39.79% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | 0.34 | 0.53 | Cheaper |
Ent. to Revenue | 2.75 | 3,967.00 | Cheaper |
PE Ratio | - | 41.03 | - |
Price to Book | 3.44 | 15.55 | Cheaper |
Dividend Yield | - | 2.20 | - |
Std. Deviation (3M) | 86.41 | 72.80 | Par |
Debt to Equity | 0.03 | -1.23 | Expensive |
Debt to Assets | 0.02 | 0.25 | Cheaper |
Market Cap | 15.90M | 3.66B | Emerging |